ArticleBreast cancer (Tokyo, Japan)2024

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).

Takahiro Nakayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.